About NIA

NACA meeting: September 24-25, 2008

Legislative Update

Significant Legislative/Executive Action

  • NIH/NIA Appropriations Update –
    1. On June 19, the House Appropriations Subcommittee on Labor, HHS, Education (Representative David Obey [D-WI], Chairman) marked up its appropriations bill for FY2009, which includes funding for NIH. The measure has a $153.1 billion discretionary spending allocation, $7.8 billion, or 5.3 percent, over the President’s request, including a 3.9 percent or $1.15 billion increase for NIH programs. Full committee action is still pending.
       
    2. The Senate appropriations measure, S. 3230 is pending floor action. This bill has an increase of $1.025 billion, or 3.5 percent, over the FY 2009 President’s Budget level for NIH. For NIA, the Senate mark is $1,077,448 million, an increase of $30 million, or 2.9 percent, over the FY 2009 President’s Budget.
       
    3. On June 30, the President signed into law H.R. 2642, the Supplemental Appropriations Act, 2008, which included $150 million for NIH for fiscal year 2008. The public law number is P.L. 110-252. (See NIA Budget Report for more details on NIH/NIA funding.)
       
    4. NIH Appropriations Hearing - On July 16, the Senate Appropriations Subcommittee on Labor, HHS, Education held an NIH overview hearing and heard testimony from Dr. Elias Zerhouni, Director, NIH, accompanied by Drs. John Niederhuber, Director, NCI, Anthony S. Fauci, Director, NIAID, Elizabeth Nabel, Director, NHLBI, and Francis Collins, Director, NHGRI.
       
  • Proposed Legislation -- S. 898, the Alzheimer’s Breakthrough Act of 2007 would increase the authorization level for Alzheimer’s disease (AD) research, and require the Director, NIA, to make supporting AD research a priority for the Institute. Both S. 898 and the House version, H.R. 1570, are still pending further action.
     
  • Congressional Briefings and Events - On June 2, Senators Barbara Mikulski [D-MD] and Benjamin Cardin [D-MD] visited NIH’s newest research facility, the Biomedical Research Center (BRC) at the Baltimore Bayview Campus. The tour and discussion was led by NIH director Dr. Elias Zerhouni, with Dr. Richard Hodes and National Institute on Drug Abuse (NIDA) Director Dr. Nora Volkow. The tour also featured a briefing by Dr. Mark Mattson of the NIA on studies in Alzheimer’s and other neurodegenerative diseases. Drs. Susan Resnick and Richard Flannery, NIA Intramural Program, also presented during a brief tour for invited press persons.

    (For more information, contact Dr. Tamara Jones, NIA Legislative Point of Contact, Ph. 301-451-8835.)